Image via Motley Fool
Legend Biotech: Capital Raising
First Beijing Investment Ltd acquired $43.78 million stake (2.3M shares) in Legend Biotech, a cancer cell therapy developer
Source: Motley Fool
The leadership read
Fresh capital usually broadens biotech & pharma leadership bench strength — scale, go-to-market and operational depth — rather than any single appointment.
Market context: Backdrop: a 98.6 (Neutral) Talent Market Index (down 1.4 on the month) with Asia activity rising (+2.4pts).
Legend Biotech: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 19 tracked companies; 0.1% of MitchelLake's Asia signal flow.
MitchelLake in this thematic
More signals across Biotech & Pharma
Geographic Expansion · Asia
Thermo Fisher Scientific →Thermo Fisher Scientific's Manila Shared Services Centre is scaling rapidly from 100 to ~700 employees by 2026, positioning itself as a high-impact regional hub for Asia-Pacific operations with focus on digital transformation and strategic value creation beyond cost efficiency.
Geographic Expansion · Asia
Promomed Group →Promomed Group (Russian pharmaceutical company) is expanding into Vietnam's pharmaceutical market with strategic partnerships. Founder Petr Bely met with Vietnam's Minister of Health to discuss long-term cooperation, technology transfer, and manufacturing operations targeting innovative drugs, biosimilars, and monoclonal antibodies
Partnership · Asia
Bristol Myers Squibb →Bristol Myers Squibb partners with China's Hengrui Pharma on a $15.2 billion deal to advance more than a dozen early-stage drugs
Ma Activity · Asia
Gilead Sciences →Gilead Sciences agreed to acquire Ouro Medicines for up to $2.18 billion, gaining rights to antibody drug licensed from China's Keymed Biosciences
Capital Raising · Americas
Sana Biotechnology, Inc. →Schedule 13G filing indicates potential significant ownership change or investment activity
Ma Activity · Americas
Biogen →Biogen agreed to acquire RayThera Inc., adding multiple immunology assets including a lead asset entering Phase 1 clinical development.
Intelligence powered by Autonodal ↗